Sat.Feb 24, 2024 - Fri.Mar 01, 2024

article thumbnail

STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest

STAT

Pfizer spent more than four hours Thursday laying out its oncology program to investors. But the company also spent some time talking about the effects of the Inflation Reduction Act on its pipeline. The drug giant, which is facing investor dissatisfaction after a year in which its stock dropped 44%, said it would be focusing on drugs that are based on proteins, not small molecule pills as it has traditionally developed.

article thumbnail

Biogen partner NeuroSense seeks a role in the ALS revolution

PharmaVoice

Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

195
195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SAEM Clinical Images Series: Neonatal Rash

ALiEM - Pharm Pearls

An 18-day-old male presented for a rash on his face for two days. The patient was born via spontaneous vaginal delivery full term without complications to a mom who has a history of genital HSV but without active lesions at delivery and on acyclovir. The patient presented with a vesicular rash on his face including around his eyes. He had conjunctival discharge noted by mom.

188
188
article thumbnail

India’s Tata Institute develops tablet for cancer recurrence prevention

Pharmaceutical Technology

India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.

143
143
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Change Healthcare cyber attack outage could persist for weeks, UnitedHealth Group executive suggests

STAT

The outage caused by the Change Healthcare cyberattack could last weeks, a top UnitedHealth executive suggested in a Tuesday conference call with hospital cybersecurity officers, according to a recording obtained by STAT. UnitedHealth Group Chief Operating Officer Dirk McMahon said the company is setting up a loan program to help providers who can’t submit insurance claims while Change is offline.

Hospitals 363
article thumbnail

Nearly 400,000 vape kits to be sent to smokers

The Pharmacist

Nearly 400,000 vape kits are set to be sent to smokers in England under the government’s swap-to-stop scheme, our sister title Healthcare Leader has exclusively revealed. At least four integrated care boards (ICBs) and more than 80 localities have expressed interest in the scheme with 379,562 ‘vape starter kits’ requested as of February 2024, data […] The post Nearly 400,000 vape kits to be sent to smokers appeared first on The Pharmacist.

125
125

More Trending

article thumbnail

Viking data suggest obesity drug could rival Zepbound, Wegovy

BioPharma Dive

The biotech’s drug led to significant weight loss in a Phase 2 trial, causing shares to double as analysts compared results to the marks set by drugs from Eli Lilly and Novo Nordisk.

122
122
article thumbnail

STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

STAT

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

Vaccines 363
article thumbnail

FDA denial could delay launch of Minerva’s schizophrenia treatment roluperidone by at least two years: GlobalData

Express Pharma

Following the news that the FDA denied approval for Minerva Neurosciences for its roluperidone for the treatment of negative symptoms in patients with schizophrenia; Christie Wong, Neurology Analyst at GlobalData, offers her view: “The FDA has issued a Complete Response Letter (CRL) for Minerva Neurosciences’ roluperidone. It follows a refusal to file in October 2022 and two FDA Type C meetings in November 2020 and March 2022.

116
116
article thumbnail

Why is pharma going gaga for radiopharmaceuticals?

pharmaphorum

Pharmaceutical companies are increasingly focusing on radiopharmaceuticals due to their potential in oncology and therapeutic applications. Learn more about why the industry is excited about radioisotopes in this article.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

CDC panel mulls changes to RSV vaccine recommendation

BioPharma Dive

The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.

Vaccines 112
article thumbnail

Amid measles outbreaks, U.K. launches vaccination ad campaign to boost childhood immunizations

STAT

LONDON — Facing a growing outbreak of measles, the U.K. has unveiled an advertising campaign aimed at boosting vaccination rates in children, which have steadily fallen over the past decade and took an even greater dip during the height of the Covid-19 pandemic. The campaign, starting March 4, features children talking about their lack of protection from infections like measles and whooping cough if they’re not vaccinated.

Immunity 362
article thumbnail

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

Pharmafile

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

111
111
article thumbnail

Planning strategies for transitioning to the Clinical Trials Regulation

pharmaphorum

There is a pressing need for companies to transition their EU clinical trials that are ongoing under the “old” regulatory framework of the Clinical Trials Directive to the Clinical Trials Regulation. The risk for those that don’t meet the 30th January 2025 deadline for transition is that they will lose their legal basis.

116
116
article thumbnail

What Your Pharmacy Can Do for National Nutrition Month

Digital Pharmacist

Did you know March is National Nutrition Month ? National Nutrition Month is an annual campaign sponsored by the Academy of Nutrition and Dietetics and it’s a great opportunity for local pharmacies to educate their patients on the importance of good nutrition, healthy diets, and exercise. Springtime, March specifically, is an excellent time of year for you to start conversations with your patients about the various foods they’re eating and how they can enhance their diets to improve

article thumbnail

More than 1 billion people have obesity, including 159 million young people, study estimates

STAT

More than 1 billion people — or one in eight people worldwide — are now estimated to have obesity, a new study finds. Obesity rates grew particularly fast among children and teens, quadrupling from 1990 to 2022, the latest year the analysis looked at, while rates among adults more than doubled. That comes to 159 million children and teens with obesity, and 879 million adults, according to the study, published Thursday in the Lancet and conducted by the NCD Risk Factor Collaboration

362
362
article thumbnail

Innovations paving the way for drug discovery of rare diseases

Express Pharma

Orphan diseases, also known as rare diseases, are a variety of conditions that affect a small percentage of the population. By definition, rare diseases are those diseases with a prevalence rate of one case in a population of 10,000 people. Rare diseases are of two types: primary and secondary. Primary rare diseases are caused due to genetic or congenital defects.

article thumbnail

Pfizer’s new cancer unit sees eight new blockbusters by 2030

pharmaphorum

Pfizer says new oncology division will generate eight new blockbusters by 2030, in first R&D update after its $43bn takeover of Seagen.

130
130
article thumbnail

Beacon Therapeutics unveils promising interim results for gene therapy AGTC-501

Pharmaceutical Technology

AGTC-501 is in Phase II development for retinitis in the SKYLINE trial (NCT03316560) and addresses unmet needs within the retinitis space

122
122
article thumbnail

CDC advisory panel says people 65 and older should get a Covid spring booster shot

STAT

An expert panel advising the Centers for Disease Control and Prevention on vaccines on Wednesday recommended that people 65 and older should get an additional Covid-19 vaccine shot this spring. The recommendation was approved by CDC Director Mandy Cohen, allowing the United States to join Canada and the United Kingdom in offering a spring booster this year to people at high risk of severe disease if they contract Covid.

Vaccines 363
article thumbnail

Nezglyal remains promising therapy despite EMA’s market authorisation refusal: GlobalData

Express Pharma

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently recommended the refusal of the marketing authorisation for Nezglyal (leriglitazone). Nezglyal is a novel orally bioavailable and selective peroxisome proliferator-activated receptor (PPAR) gamma agonist that is intended for the treatment of cerebral adrenoleukodystrophy (cALD).

109
109
article thumbnail

Rare Disease Day 2024 – The importance of shining a light on rare diseases

pharmaphorum

Rare Disease Day 2024 is an important opportunity to raise awareness about rare diseases and the need for research, diagnosis, and treatment options like orphan drugs. Learn the significance of shining a light on rare diseases.

116
116
article thumbnail

Obesity drug from Boehringer, Zealand succeeds in MASH trial

BioPharma Dive

Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.

114
114
article thumbnail

‘Brain fog’ is one of Covid-19’s most daunting symptoms. A new study measures its impact

STAT

Of all the lingering symptoms of long Covid , difficulty focusing and thinking, known as brain fog , may be the most frightening and baffling. A new study published Wednesday in the New England Journal of Medicine, which looks at how much cognition is impaired in the months after a coronavirus infection, shows that Covid-19’s impact can be measured in the equivalent of IQ points.

Hospitals 363
article thumbnail

Takeda partner with Biological E. to accelerate access to dengue vaccine

Express Pharma

The partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and Takeda’s long-term partnership with IDT Biologika GmbH Takeda and Biological E. Limited (BE) has announced a strategic partnership to accelerate access to QDENGA▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs).

Vaccines 110
article thumbnail

Power of digital technology and partnership to accelerate delivery of new medicines to patients

pharmaphorum

Discover how digital technology and strategic partnerships are revolutionising the pharmaceutical industry, enabling faster delivery of life-saving medicines to patients, while advancing humanity's fight against diseases.

116
116
article thumbnail

Gritstone to lay off 40% of workforce after costly study delay

BioPharma Dive

The restructuring comes ahead of a key study readout for Gritstone, which, like Moderna, is developing a type of personalized vaccine for cancer.

Vaccines 117
article thumbnail

STAT+: White House to hold a listening session on reforming pharmacy benefit managers

STAT

In a bid to combat prescription drug costs, the White House will hold a listening session on Monday in search of ways to reform pharmacy benefit managers , according to people familiar with the plans. The list of attendees includes representatives from the federal government and industry, who are expected to provide insights into how the largest pharmacy benefit managers determine which medicines are covered by insurers and employers, as well as prices that are paid at pharmacy counters.

363
363
article thumbnail

Zeno Health secures $25 million in Series C funding

Express Pharma

Zeno Health, an omnichannel platform for generic medicines, announced the successful closure of its Series C funding round, securing a total of $5 million. The round has been led by Korean private equity investor STIC Investments. Existing Zeno Health investor Lightbox was also a significant participant in the round. The company informed that the $25 million capital injection will be pivotal in propelling Zeno Health’s initiatives to reach more consumers, expand its footprint, and further

article thumbnail

AbbVie inks $713m deal for OSE chronic inflammation drug

pharmaphorum

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics. There’s another $665 million in potential milestones and a royalty tied to the deal, which focuses on OSE-230, billed as a potentially first-in-class activator of ChemR23, a G-protein coupled receptor (GPCR) found on some white blood cells.

114
114
article thumbnail

Shell refines its focus on the hydrogen market

Fuld & Company Blog

Last week, Shell made a move that looked very much like a major nail in the coffin of the hydrogen passenger car market. In October 2023, Shell quietly shut down its three UK hydrogen filling stations for passenger cars. Following this, last week, it did the same in California. Originally planning to establish 48 stations across the state, Shell scrapped these plans last year and announced the closure of all five passenger car stations, while maintaining its three heavy-duty hydrogen stations

105
105
article thumbnail

Opinion: Medicare Advantage is bad for patients and bad for investors

STAT

In 2023, enrollment in Medicare Advantage, the version of Medicare run by private insurers, surpassed 50% of eligible beneficiaries for the very first time. Going by this headline, or perhaps the predictable flood of advertisements for plans during the fall’s open enrollment period, you might be fooled into thinking 2023 was MA’s best year yet.

363
363
article thumbnail

Suven, Cohance announce merger

Express Pharma

Suven Pharmaceuticals and Cohance Lifesciences announced a proposed scheme of amalgamation for the merger of Cohance with Suven. The merged entity is expected to be a leading integrated CDMO players in India with an expanded capacity to ~2,650 kL and a broadened customer base. Cohance is a CDMO and merchant API platform with strong capabilities in select low-mid volume molecules and its antibody drug conjugates (ADC) platform.

104
104
article thumbnail

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

pharmaphorum

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

113
113
article thumbnail

Baseimmune secures funding for vaccine development

Pharmaceutical Business Review

The investment, led by MSD Global Health Innovation Fund and IQ Capital, with contributions from Hoxton Ventures, Creator Fund, Beast Ventures, and Maki.vc, will expedite the progress of Baseimmune’s technology and vaccine candidates. The capital infusion will accelerate the preclinical development of Baseimmune’s three vaccine candidates targeting African swine fever, coronavirus, and malaria.

Vaccines 105